- Telo Genomics Corp. (TELO) will evaluate its TeloView platform to identify multiple myeloma (MM) patients at high risk of developing treatment resistance
- Telo Genomics is carrying out the study in collaboration with the Mayo Clinic
- It is the second study by the two organizations to evaluate the company’s prognostic technology to address multiple unmet clinical needs in MM
- MM is a highly challenging and deadly blood cancer that forms in plasma cells
- Telo Genomics Corp. is a biotech company Telo Genomics which engages in the development and commercialization of diagnostic and prognostic products
- Telo Genomics Corp. was down 10.00 per cent, trading at $0.36 at 11:50 AM ET
Telo Genomics (TELO) has begun to evaluate its TeloView platform to identify multiple myeloma (MM) patients at high risk of developing treatment resistance.
This study, which the organization is carrying out in collaboration with the Mayo Clinic, is the second study to evaluate the company’s prognostic technology to address multiple unmet clinical needs in MM.
MM is a highly challenging and deadly blood cancer that forms in plasma cells, a type of white blood cell. Symptoms of MM include bone pain, frequent infections, fatigue, and weight loss.
There are currently several combinations of drugs in clinical use for the treatment of MM, and most patients initially respond to treatment and enter remission.
However, disease remission is typically followed by treatment resistance and relapse, which can occur from as early as three months from initiation of treatment until 24 months.
Identifying patients who will develop drug resistance before relapse is a critical unmet need in managing MM. Addressing this unmet need will allow healthcare providers to identify high-risk drug resistance patients and modify their treatment regimens accordingly.
“We are excited to launch this drug resistance study for multiple myeloma patients in collaboration with the Mayo Clinic,” noted Sherif Louis, TELO’s CEO.
“The development of this test, in addition to TELO’s lead product for SMM, has the potential to position our TeloView platform as a powerful prognostic tool to address multiple unmet clinical needs for the management of multiple myeloma,” he added.
Telo Genomics Corp is a personalized medicine company which engages in the development and commercialization of diagnostic and prognostic products.
Telo Genomics Corp. was down 10.00 per cent, trading at $0.36 at 11:50 AM ET.